The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis.
The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis. Biosci Trends. 2019 Oct 14;: Authors: Han T, Yang X, Zhang Y, Li G, Liu L, Chen T, Zheng Z Abstract Transcatheter arterial chemoembolization (TACE) plays an important role in the treatment of unresectable liver cancer. We conducted this meta-analysis to compare the clinical safety and efficacy of conventional TACE (C-TACE) and drug-eluting beads (DEB)-TACE. A search for those procedures was performed using the PubMed, EMBASE, and Cochrane Library databases. A meta-analysis of patients who underwent C-TACE or DEB-TACE was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Of 334 studies, 30 were analyzed. The complete response rate, disease control rate, objective response rate, 3-year survival rate, and non-response rate were significantly higher in patients who underwent DEB-TACE than those in patients who underwent C-TACE. The 1-year survival rate, 2-year survival rate, 30-day mortality rate, complete response rate, disease control rate, complete necrosis rate, non-response rate, objective response rate, progressive disease rate, and recurrence did not differ significantly between patients who underwent C-TACE and patients who underwent DEB-TACE. Patients who undergo DEB-TACE might have a higher complete response ...
Publication date: March 2020Source: Journal of Vascular and Interventional Radiology, Volume 31, Issue 3, SupplementAuthor(s): Y. Wang, K. Schachtschneider, Y. Huang, R. Gaba, P. Nguyen, P. Yen, M. Sverdlov, G. Guzman, R. Lokken
AJ Gunn, M.D. graduated magna cum laude from Brigham Young University in Provo, UT, earning a BS in exercise physiology with a minor in sociology. He then returned home to South Dakota to attend medical school at the University of South Dakota. During medical school, he participated in the competitive Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program and was awarded the Donald L. Alcott, M.D. Award for Clinical Promise. He graduated summa cum laude in 2009. He completed his diagnostic radiology residency at the Massachusetts General Hospital of Harvard Medical School in Boston,...
To compare the all-cause survival, cancer-specific survival and progression-free survival of surgical resection (SR) versus ablation (AB) for small hepatocellular carcinoma.
To identify key clinical and imaging predictors of survival in patients undergoing Yttrium-90 radioembolization (Y90-RE) for advanced, Barcelona Clinic Liver Cancer (BCLC) C, hepatocellular carcinoma (HCC).
A provision in the Affordable Care Act (ACA) expanded Medicaid eligibility in participating states to low-income individuals with incomes up to 138% of the federal poverty level. Medicaid expansion has been associated with earlier cancer stage at diagnosis, which we hypothesized may alter treatment patterns for patients with early stage renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and non-small lung cancer (NSCLC).
We present our experience of sequential Y90 RE and portal vein embolization.
Hepatocellular Carcinoma (HCC) has become the fastest growing lethal cancer in the United States. Current selection of a specific locoregional treatment for HCC is based on imaging findings and operator experience. There remains a clear lack of reliable objective criteria for selection of an appropriate loco regional treatment. Non-invasive serological biomarkers combined with imaging techniques can be a valuable tool for determining appropriate locoregional therapies. The purpose of this study is to identify mRNA encoded prognostic biomarkers for precision treatment and outcome prediction.
Microwave ablation (MWA) has been shown to be effective in treatment of primary hepatic cellular carcinoma (HCC) and liver metastasis from colorectal cancer. The purpose of this study is to demonstrate the safety and efficacy of MWA of liver lesions including primary HCC and liver metastasis with final ablation zone that is ≤ 5 mm from the pericardium.
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCC) together account for almost all cases of primary liver cancers. Differentiation between the two cancers before treatment has significant implication for interventional radiologists, who are often involved in biopsy and treatment of both lesions. The ability to differentiate HCC from CCC on imaging could decrease morbidity, decrease cost and improve clinical decision making. To this end, we intend to use radiomics to classify cases of HCC and CCC from patient MRI scans.
The current Barcelona Clinic Liver Cancer (BCLC) guidelines recommend systemic therapy as the mainstay treatment for advanced stage (BCLC-C) Hepatocellular Carcinoma (HCC) while reserving Transarterial Chemoembolization for intermediate stage (BCLC-B). Our goal is to evaluate survival benefits of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) in BCLC-C patients.